OCULAR THERAPEUTIX INC (OCUL) Forecast, Price Target & Analyst Ratings
NASDAQ:OCUL • US67576A1007
10.173 USD
-0.16 (-1.52%)
Last: Mar 6, 2026, 03:46 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for OCULAR THERAPEUTIX INC (OCUL).
Forecast Snapshot
Consensus Price Target
$25.50
+ 150.66% Upside
Next Earnings Forecast
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$0.32
Revenue Estimate12.812M
ChartMill Buy Consensus
86.32%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$25.50
Upside
+ 150.66%
From current price of $10.17 to mean target of $25.50, Based on 19 analyst forecasts
Low
$18.18
Median
$24.48
High
$35.70
Price Target Revisions
1 Month
2.74%
3 Months
11.94%
Price Target Summary
19 analysts have analysed OCUL and the average price target is 25.5 USD. This implies a price increase of 150.66% is expected in the next year compared to the current price of 10.173.
The average price target has been revised upward by 11.94% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.32%
OCUL was analyzed by 19 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about OCUL.
In the previous month the buy percentage consensus was at a similar level.
OCUL was analyzed by 19 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-03 | Clear Street | Maintains | Buy -> Buy |
| 2026-02-20 | Needham | Maintains | Buy -> Buy |
| 2026-02-18 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-08 | Needham | Reiterate | Buy -> Buy |
| 2025-12-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-30 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-03 | Baird | Maintains | Outperform -> Outperform |
| 2025-10-03 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-02 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-01 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-10-01 | Needham | Maintains | Buy -> Buy |
| 2025-09-15 | Chardan Capital | Initiate | Buy |
| 2025-08-06 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-08-05 | Needham | Maintains | Buy -> Buy |
| 2025-05-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-06 | Needham | Maintains | Buy -> Buy |
| 2025-04-08 | William Blair | Initiate | Outperform |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-03-18 | RBC Capital | Initiate | Outperform |
| 2025-03-11 | Needham | Initiate | Buy |
| 2025-03-04 | Citizens Capital Markets | Maintains | Market Outperform -> Market Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$0.32
Revenue Estimate12.812M
Revenue Q2Q19.76%
EPS Q2Q14.79%
Number of Analysts15
Next Earnings Revisions
Revenue (1 Month)
-10.66%
Revenue (3 Months)
-11.66%
EPS (1 Month)
8.85%
EPS (3 Months)
7.33%
Next Earnings Summary
OCUL is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.32 USD and the consensus revenue estimate is 12.81M USD.
The next earnings revenue estimate has been revised downward by 11.66% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 58.443M 13.50% | 63.723M 9.03% | 51.951M -18.47% | 57.148M 10.00% | 115.83M 102.68% | 305.4M 163.66% | 587.89M 92.50% | 968.87M 64.80% | 1.333B 37.58% | 1.732B 29.93% | 2.092B 20.79% | |
| EBITDA YoY % growth | -79.399M -3.74% | -167.995M -111.58% | -265.694M -58.16% | -292.883M -10.23% | -127.561M 56.45% | 41.738M 132.72% | 255.43M 511.98% | 568.66M 122.63% | 730.74M 28.50% | 820.9M 12.34% | 829.43M 1.04% | |
| EBIT YoY % growth | -82.382M -4.75% | -171.781M -108.52% | -270.017M -57.19% | -327.384M -21.25% | -282.853M 13.60% | -282.99M -0.05% | 12.464M 104.40% | 284.36M 2,181.45% | 558.15M 96.28% | 853.82M 52.97% | 1.139B 33.40% | |
| Operating Margin | -140.96% | -269.57% | -519.75% | -572.87% | -244.20% | -92.66% | 2.12% | 29.35% | 41.87% | 49.30% | 54.45% | |
| EPS YoY % growth | -1.17 -21.87% | -1.47 -25.64% | -1.44 2.04% | -1.46 -1.40% | -1.13 22.72% | -0.63 43.95% | 0.54 185.48% | 2.34 332.08% | 3.42 46.29% | 3.91 14.33% | 4.23 8.36% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.32 14.79% | -0.33 14.58% | -0.38 -0.08% | -0.39 -33.41% | -0.29 11.80% | -0.21 35.71% | -0.09 75.86% | -0.04 89.45% |
| Revenue Q2Q % growth | 12.812M 19.76% | 14.103M 4.78% | 15.568M 7.04% | 16.642M 25.60% | 21.191M 65.40% | 33.017M 134.11% | 54.096M 247.48% | 67.565M 305.99% |
| EBITDA Q2Q % growth | -72.134M -14.62% | -73.511M -12.00% | -75.205M -14.60% | -76.663M -17.16% | -63.791M 11.57% | -47.501M 35.38% | -22.022M 70.72% | -8.211M 89.29% |
| EBIT Q2Q % growth | -75.223M -17.69% | -78.542M -16.12% | -83.112M -20.98% | -86.307M -23.72% | -63.791M 15.20% | -47.501M 39.52% | -22.022M 73.50% | -8.211M 90.49% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
16.00%
EPS Next 5 Year
29.36%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
76.14%
Revenue Next 5 Year
76.93%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
29.09%
EBIT Next 5 Year
32.32%
OCULAR THERAPEUTIX INC / OCUL Forecast FAQ
What is the average price target for OCULAR THERAPEUTIX INC (OCUL) stock?
19 analysts have analysed OCUL and the average price target is 25.5 USD. This implies a price increase of 150.66% is expected in the next year compared to the current price of 10.173.
Can you provide the upcoming earnings date for OCULAR THERAPEUTIX INC?
OCULAR THERAPEUTIX INC (OCUL) will report earnings on 2026-05-04, after the market close.
What are the consensus estimates for OCULAR THERAPEUTIX INC (OCUL) next earnings?
The consensus EPS estimate for the next earnings of OCULAR THERAPEUTIX INC (OCUL) is -0.32 USD and the consensus revenue estimate is 12.81M USD.
Can you provide the expected long term growth rate for OCULAR THERAPEUTIX INC stock?
The expected long term growth rate for OCULAR THERAPEUTIX INC (OCUL) is 76.14%.